ArticleThrombosis2011
Thrombocytosis: diagnostic evaluation, thrombotic risk stratification, and risk-based management strategies.
Article in Thrombosis, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 141 citations in OpenAlex.
- Optimized Test Utilization Significantly Increased the Positive Detection Rate for Myeloproliferative Neoplasms.Cancers · 2026Article
- Article
- Isolated Ulnar Artery Occlusion with Concurrent Internal Jugular Vein Thrombosis in Severe Iron-Deficiency Anaemia.European journal of case reports in internal medicine · 2026Article
- Next Generation Sequencing Identifies Subgroups of Patients With Triple Negative Primary Thrombocytosis With Different Clinical Thrombotic Outcomes.International journal of laboratory hematology · 2025Article
- Visualization of Critical Limits and Critical Values Facilitates Interpretation.Diagnostics (Basel, Switzerland) · 2025Article
- Human Disabled-2 regulates thromboxane ANature communications · 2024Article
- Etiology and clinical course of severe and extreme thrombocytosis in children: a retrospective single-center study.European journal of pediatrics · 2024Article
- Platelet Count Normalization Following Romosozumab Treatment for Osteoporosis in Patient with Immune Thrombocytopenic Purpura: A Case Report and Literature Review.Journal of bone metabolism · 2024Article
- Platelet count in heart failure patients undergoing left ventricular assist device.ESC heart failure · 2024Article
- Iron deficiency-induced thrombocytosis presenting with blue toe syndrome.Clinical case reports · 2024Article
- An Approach to the Investigation of Thrombocytosis: Differentiating between Essential Thrombocythemia and Secondary Thrombocytosis.Advances in hematology · 2024Article
- The Important Role of Preoperative D-Dimer in Constrictive Pericarditis.Therapeutics and clinical risk management · 2024Article
- A Case of JAK2V617F-Negative Myeloproliferative Neoplasm in a Young Female Presenting With Extreme Thrombocytosis.Cureus · 2023Article
- Secondary thrombocythemia with ST-segment elevation myocardial infarction as the first manifestation: a case report.Annals of medicine and surgery (2012) · 2023Article
- Integrated Approach to Highlighting the Molecular Bases of a Deep Vein Thrombosis Event in an Elite Basketball Athlete.International journal of molecular sciences · 2023Article
- Clinical prediction rule for bacterial arthritis: Chi-squared automatic interaction detector decision tree analysis model.SAGE open medicine · 2023Article
- Usefulness of Complete Blood Count (CBC) to Assess Cardiovascular and Metabolic Diseases in Clinical Settings: A Comprehensive Literature Review.Biomedicines · 2022Review
- High rate of extreme thrombocytosis indicates bone marrow hyperactivity and splenic dysfunction among congenital diaphragmatic hernia patients.Platelets · 2022Article
- Article
- Janus Kinase-2 V617F Mutation and Antiphospholipid Syndrome in Cerebral Sinus Venous Thrombosis: Natural History and Retrospective Bicenter Analysis.Frontiers in neurology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thrombocytosis is a commonly encountered clinical scenario, with a large proportion of cases discovered incidentally. The differential diagnosis for thrombocytosis is broad and the diagnostic process can be challenging. Thrombocytosis can be spurious, attributed to a reactive process or due to clonal disorder. This distinction is important as it carries implications for evaluation, prognosis, and treatment. Clonal thrombocytosis associated with the myeloproliferative neoplasms, especially essential thrombocythemia and polycythemia vera, carries a unique prognostic profile, with a markedly increased risk of thrombosis. This risk is the driving factor behind treatment strategies in these disorders. Clinical trials utilizing targeted therapies in thrombocytosis are ongoing with new therapeutic targets waiting to be explored. This paper will outline the mechanisms underlying thrombocytosis, the diagnostic evaluation of thrombocytosis, complications of thrombocytosis with a special focus on thrombotic risk as well as treatment options for clonal processes leading to thrombocytosis, including essential thrombocythemia and polycythemia vera.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.